Prescription medication · Calcium Channel Blocker
nisoldipine
Also sold as Sular. Nisoldipine extended-release tablets are used to treat high blood pressure.
Data updated 2026-05-15
- 1,191
- FDA reportsRarely reported
- 2
- InteractionsFew interactions
- $3.62
- Generic price (NADAC)
What the data shows
nisoldipine (Sular) is a prescription Calcium Channel Blocker, among the least-reported drugs the FDA tracks (1,191 FDA reports), with 2 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
nisoldipine (Sular) is a prescription Calcium Channel Blocker. Nisoldipine extended-release tablets are used to treat high blood pressure.
Nisoldipine is a medicine to treat high blood pressure. It belongs to a class of drugs called calcium channel blockers.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$3.62/unit
Generic Available
Yes (2 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Nisoldipine extended-release tablets are used to treat high blood pressure.
Common side effects
Swelling in your legs or ankles, Headache, Dizziness
Key warnings
If you are allergic to dihydropyridine calcium channel blockers, you should not take this medicine.
The sections below are summarized in plain English from nisoldipine's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Nisoldipine blocks calcium from entering certain cells. This helps to relax and widen blood vessels. As a result, blood can flow more easily, which lowers blood pressure.
Side Effects (from patient reports)
Based on 1,191 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for nisoldipine, by number of reports
- Nausea
Nausea
88 reports
- Dizziness
Dizziness
77 reports
- Headache
Headache
76 reports
- Fatigue
Fatigue
74 reports
- Renal Failure
Renal Failure
65 reports
- Pain
Pain
64 reports
- Dyspnoea
Dyspnoea
63 reports
- Asthenia
Asthenia
62 reports
- Diarrhoea
Diarrhoea
59 reports
- Anxiety
Anxiety
54 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for nisoldipine each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where nisoldipine sits
nisoldipine has more FDA adverse-event reports than 8% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is nisoldipine; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 1,191 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
1,191
Reports Mentioning Death
123
10.3% of reports — not proof of cause
Hospitalization Reports
394
Top Indication
Hypertension
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | NAUSEA | 88 |
| 3 | DIZZINESS | 77 |
| 4 | HEADACHE | 76 |
| 5 | FATIGUE | 74 |
| 6 | RENAL FAILURE | 65 |
| 7 | PAIN | 64 |
| 8 | DYSPNOEA | 63 |
| 9 | ASTHENIA | 62 |
| 10 | DIARRHOEA | 59 |
| 11 | ANXIETY | 54 |
| 12 | MYOCARDIAL INFARCTION | 54 |
| 13 | OEDEMA PERIPHERAL | 54 |
| 14 | HYPERTENSION | 50 |
| 15 | PRURITUS | 49 |
| 16 | CHRONIC KIDNEY DISEASE | 46 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
If you are allergic to dihydropyridine calcium channel blockers, you should not take this medicine.
Known Drug Interactions
Calcium Channel Blockers Felodipine a Nisoldipine Contraindicated during and 2 weeks after itraconazole treatment.
Mechanism: Itraconazole blocks the enzymes that clear nisoldipine from your body, causing the drug to build up to unsafe levels.
Phenytoin when given with the combination of fosamprenavir and ritonavir may increase the concentration of amprenavir Calcium channel blockers Nifedipine, nimodipine, nisoldipine, verapamil Other Albendazole (decreases active metabolite), chlorpropamide, clozapine, cyclosporine, digoxin, disopyramide, folic acid, methadone, mexiletine, praziquantel, quetiapine a The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels is unpredictable 7.3 Drug/Laboratory Test Interactions Care should be taken when using immunoanalytical methods to measure serum phenytoin...
Mechanism: Phenytoin makes your body clear nisoldipine out of your system more quickly, which can make this blood pressure medicine less effective.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I cut the pill in half?
What should I avoid while taking this medicine?
What is the starting dose?
What is the usual maintenance dose?
Can I take this with other blood pressure medicines?
What if I am over 65 or have liver problems?
What should I do if I experience swelling in my ankles?
How long will I need to take this medication?
What do the tablets look like?
What if I think I'm having a serious side effect?
What are the common side effects of nisoldipine?
Does nisoldipine interact with other medications?
What drug class is nisoldipine?
What pregnancy or breastfeeding source fields are listed for nisoldipine?
Related Medications in Calcium Channel Blocker
Other drugs grouped near nisoldipine - same-class peers and common alternatives.
acebutolol
Sectral
Acebutolol is a medicine that helps lower blood pressure and control irregular heartbeats.
Compare with nisoldipine →
aliskiren
Tekturna
Tekturna is a medicine used to treat high blood pressure.
Compare with nisoldipine →
amiloride
Midamor
Amiloride is a water pill that helps your body hold onto potassium.
Compare with nisoldipine →
amlodipine
Norvasc
Amlodipine (Norvasc) is a drug that lowers blood pressure and treats chest pain.
Compare with nisoldipine →
amlodipine/benazepril
Lotrel
Lotrel is a combination medicine that contains amlodipine and benazepril.
Compare with nisoldipine →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for nisoldipine: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 1,191.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 10.33%.
- labetalol Δ 0.00 pts · 12,726 reports · Alpha/Beta-Blocker 10.33%death share
- disulfiram Δ 0.01 pts · 1,076 reports · Aldehyde Dehydrogenase Inhibitor 10.32%death share
- duloxetine Δ 0.02 pts · 65,067 reports · Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) 10.31%death share
- chlorzoxazone Δ 0.02 pts · 1,256 reports · Muscle Relaxant 10.35%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on nisoldipine
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for nisoldipine
The FDA label for nisoldipine (sold under brand names such as Sular) classifies it as a prescription-only medication in the Calcium Channel Blocker class. Nisoldipine extended-release tablets are used to treat high blood pressure. Official labeling lists 5 commonly reported side effects, including Swelling in your legs or ankles, Headache, Dizziness.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,191 voluntary reports. The database also lists 2 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS shows a generic unit cost of $3.62.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: September 30, 2022
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages